Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Cyclo Therapeutics (CYTH) PT Lowered to $0.95 at Ascendiant Capital
August 26, 2024 5:03 AM EDTAscendiant Capital analyst Lucas Ward lowered the price target on Cyclo Therapeutics (NASDAQ: CYTH) to $0.95 (from $2.60) while maintaining a Buy rating.
The analyst comments "Company completes enrollment in phase 3 trial, affirms regulatory timeline: On May 30, the company announced it has completed enrollment for its... More
